2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1552

Illness Perceptions in Rheumatoid Arthritis: A Comparison of Canadian and Nigerian Patients
Abstract Number: 1735

Imaging and Clinical Factors Associated with Subchondral Sacroiliac Fatty Marrow in Axial Spondyloarthritis
Abstract Number: 2110

Imaging and Safety Assessments Following Treatment with Febuxostat and Placebo for 2 Years in Subjects with Early Gout
Abstract Number: 1993

Imaging Findings of Cerebral Amyloid Angiopathy, Abeta-Related Angiitis (ABRA) and Cerebral Amyloid Angiopathy-Related Inflammation: A Single Institution 25 Year Experience
Abstract Number: 1341

Imaging Growing Joints By Diffraction Enhanced-Computed Tomography Using a Synchrotron Light Source
Abstract Number: 2088

Immature Dendritic Are Potent OC Precursors in RA and Are Targeted By RA-Specific Antibodies
Abstract Number: 2709

Immediate Release of Peripheral Neutrophil Myeloperoxidase and Elastase and Formation of Extracellular Traps to Cigarette Smoking in Rheumatoid Arthritis
Abstract Number: 83

Immediate Benefits of a Multidisciplinary Educational Program for Fibromyalgia on Patients’ Pain Related Self-Efficacy and Health Locus of Control
Abstract Number: 2096

Immune Dysregulation in Patients with TRNT1 Deficiency
Abstract Number: 2563

Immune Regulation By Migrating Mesenchymal Stem Cells Ameliorate Inflammatory Arthritis in Mice
Abstract Number: 1403

Immune Related Adverse Events Associated with Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review of Case Reports
Abstract Number: 2000

Immune Response Against Â Î²2GPI Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome
Abstract Number: 531

Immune Responses to Mycobacterium Heat Shock Protein 70 Accompany Self-Reactivity to Human Bip in Rheumatoid Arthritis
Abstract Number: 3259

Immunoablation Followed By Autologous Stem Cell Transplantation in Systemic Sclerosis Patients Decreases Significantly the Interferon Signatrue
Abstract Number: 3114

Immunogenicity of Subcutaneous and Intravenous Tocilizumab As Monotherapy or in Combination with Dmards

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].